Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
While immune checkpoint inhibitor (ICI) therapy has excellent efficacy in treating multiple cancers, some patients experience accelerated disease progression, defined as hyper-progressive disease (HPD). However, the characteristics of HPD, especially in patients with non-small-cell lung cancer (NSCLC), remain to be elucidated. We report about an advanced NSCLC patient with striking disease progression, defined as HPD by existing standards, after the administration of pembrolizumab. We also reviewed related studies to discuss the definition, relative factors, and prognosis of HPD. This case of NSCLC with HPD had a series of characteristics not widely described in HPD cases previously reported, suggesting the potential complexity of this phenomenon and the necessity to study its characteristics and to more closely monitor patients who are administered ICIs.